Alector, Inc.
ALEC
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial forā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.28
Price-1.54%
-$0.02
1Y
Price
Market Cap
$129.552m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-433.5%
EBITDA Margin-387.7%
Net Profit Margin-623.0%
Free Cash Flow MarginRevenue
$81.130m
-19.3%
1y CAGR-14.4%
3y CAGR-19.6%
5y CAGREarnings
-$115.289m
+3.2%
1y CAGR+4.7%
3y CAGR-63.2%
5y CAGREPS
-$1.17
+4.9%
1y CAGR+9.9%
3y CAGR-57.6%
5y CAGRBook Value
$71.175m
$356.422m
Assets$285.247m
Liabilities$39.483m
DebtDebt to Assets
11.1%
-0.3x
Debt to EBITDAFree Cash Flow
-$216.006m
+6.6%
1y CAGR-226.8%
3y CAGR-197.2%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company